ArticleNPJ precision oncology2026
Earlier postoperative ctDNA detection predicts recurrence and adjuvant therapy benefit in stage II-III colorectal cancer.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Detection of postoperative minimal residual disease (MRD) using circulating tumor DNA (ctDNA) accurately predicts cancer recurrence and may even guide adjuvant chemotherapy. Cost-effective and easily implementable assays capable of detecting MRD early (within days after surgery) will drive wider clinical adaptation. We developed a rapid, single-tube multiplex quantitative methylation-specific PCR (mqMSP) assay targeting 10 rigorously screened methylation markers. In a preoperative cohort, mqMSP achieved 100% specificity in 96 controls, with an overall sensitivity of 73.1% for CRC. In a postoperative cohort of 246 stage II-III CRC patients with a long follow-up time (7-96 months, median: 48 months), we demonstrated that ctDNA detection by mqMSP at an early timepoint (median: 5 days after surgery) predicted worse disease-free survival (HR 7.43, P < 0.0001) and overall survival (HR 8.81, P < 0.0001). Benefit from completion of recommended adjuvant therapy was only seen for ctDNA-positive patients, but not for ctDNA-negative patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.